HeberFERON, a new formulation of IFNs with improved pharmacodynamics. Perspective for cancer treatment

Publication date: Available online 4 May 2018
Source:Seminars in Oncology
Author(s): Bello-Rivero Iraldo, Garcia-Vega Yanelda, Duncan-Roberts Yaquelin, Vazquez-Blonquist Dania, Hector Santana Milian, Besada-Perez Vladimir, Rios-Cabrera Margarita
The rational combination of recombinant IFN-α2b and IFN-γ resulted in a new formulation of IFNs (HeberFERON) with improved pharmacodynamics. In basal cell carcinomas HeberFERON produces a more rapid antitumor effect and results in a larger number of complete responses. In patients with glioblastoma multiforme, the administration of HeberFERON after surgery and radiotherapy results in an estimated overall survival of 19 months. Patients with state III or IV renal cell carcinoma  also ppear to benefit from the intravenous administration of HeberFERON, with prolongation of survival and a good quality of live. HeberFERON offers a promising alternative formulation of IFNs for the treatment of cancer with a very favorable safety profile.



https://ift.tt/2IQVGSU